Introduction
The erythrocyte sedimentation rate (ESR) is a simple and inexpensive laboratory test for assessing the inflammatory response. It is an indirect, qualitative measure of fibrinogen and other acute phase protein concentrations in plasma. 1 ESR can be greatly influenced by the size, shape, and number of erythrocytes, as well as by other plasma constituents such as immunoglobulins. Erythrocyte aggregation is affected by two major factors: red cell surface charges and frictional forces around the red cell. The erythrocytes normally have net negative charges and, therefore, repel each other. High molecular weight proteins, especially when positively charged, increase viscosity and favor rouleaux formation and thus raise the ESR. Fibrinogen, the most abundant acute phase reactant, has the greatest effect on the elevation of ESR when compared with other acute phase proteins. 2, 3 Ultimately, ESR levels are influenced by a wide range of factors, many of them unrelated to inflammation. Hypoalbuminemia, hypercholesterolemia, and hypergammaglobulinemia may increase ESR. 4 In anemia, the velocity of the upward flow of plasma is altered when the hematocrit is reduced so that red blood cells sediment faster. However, in strongly direct Coombs-positive anemia, the density gradient between plasma and erythrocytes is lost and the ESR is low. 5 Normal ESR values increase with age. 6 In African Americans, normal values of the ESR are at least 2-13 mm/h higher even after correcting for age, hemoglobin concentration, and certain chronic diseases such as malignancies, infections, connective tissue diseases and chronic renal insufficiency. 7, 8 ESR elevation is common in systemic lupus erythematosus (SLE). It was found in 56% of patients with SLE in a survey of 570 patients at Cedars Sinai between 1980 and 1989. 9 It is often measured as a potential indicator of disease activity. For this reason, it was included in the Systemic Lupus Activity Measure (SLAM). 10 However, there is significant uncertainty with regard to the utility of this test in the assessment of SLE activity. Previous studies have been limited by inconsistent patient follow-up, lack of adjustment for confounding factors and coexistent conditions and use of non-validated SLE activity scales. Here we report on the utility of ESR as a marker and predictor of disease activity in the Hopkins Lupus Cohort.
Patients and methods
As previously described, 11 the Hopkins Lupus Cohort is a prospective cohort study of predictors of lupus flare, atherosclerosis, and health status in SLE. The study cohort includes all patients at the Hopkins Lupus Center who have a clinical diagnosis of SLE and give informed consent to participate in the study. Subjects enrolled in the cohort are followed quarterly, or more frequently if clinically necessary. The clinical features, laboratory testing, and damage accrual data are recorded at the time of entry into the cohort and are updated at subsequent visits. The Hopkins Lupus Cohort has been approved by the Johns Hopkins University School of Medicine Institutional Review Board and complies with the Health Insurance Portability and Accountability Act.
ESR was measured by an InteRRliner ESR Analyzer automated system. The InteRRliner is a fully automated rack system utilizing the Westergren method for erythrocyte sedimentation analysis. A full 3 or 5 ml tube of venous blood collected in EDTA was delivered to the laboratory within 4 h of collection, or within 6 h if the specimen was refrigerated. The EDTA specimen was mixed and automatically diluted during aspiration to the next available glass pipette. The pipette travelled around the belt for 60 min, at which time the measuring sensor determined the sedimentation rate. The result was sent to the printer and host computer for verification. Quality control of the system was performed with every shift, three times daily, by using the SEDRite Plus Controls and verifying them with the Sysmex autoverification program. Normal values for those younger than 50 years of age were 4-25 mm/h for women and 1-15 mm/h for men, while for those older than 50, normal values were between 4-30 mm/h for women and 1-20 mm/h for men.
In case the automated system failed or did not pass quality control, a manual ESR measurement based on a modified Westergren method was used as a backup. Four parts of anticoagulated whole blood were added to one part 0.85% saline. The specimen was thoroughly mixed by a minimum of eight repeated inversions. The Dispette Tube was inserted to the bottom of the reservoir. The full Dispette assembly was placed in the leveled Dispette stand at a 90 angle. At the end of the 60 min, the result was read by observing the number of millimeters the RBC column has dropped from the zero mark printed on the Dispette2 pipette. 12 Normal values were identical to the values used by the automated system.
Patients and activity indices
Some 95% of patients fulfilled four or more of the American College of Rheumatology (ACR) 1982 revised classification criteria for SLE. 13, 14 Disease activity was measured with the Physician Global Assessment (PGA), Lupus Activity Index (LAI), 15 and the SELENA revision of the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index instrument score (SELENA-SLEDAI). 16 The LAI is both a global and organ-specific activity score assessing activity over the previous 2 weeks. The index consists of five sections and includes eight organ systems and three laboratory measures, including anti-dsDNA. The index includes the PGA as well as a score for treatment with glucocorticoids and immunosuppressive drugs. The index allows grading for severity based on physician judgment. The overall score ranges from 0-3, and is the mean of the PGA, physician judgment of the severity of clinical manifestations, degree of laboratory manifestations, and treatment. 15 We used the organ-specific visual analogue scales (VAS) of the LAI in this study.
The SELENA revision of the SELENA-SLEDAI instrument score measures disease activity within the last 10 days. It includes 24 clinical and laboratory variables that are weighted by type of manifestation as well as the PGA and a flare index. Disease activity may, in theory, range from 0-105. 16 
Statistical methods
To assess the association between ESR level, and levels of disease activity at the same visit, we analyzed data from all cohort visits, excluding visits in which patients had cancer, infection, pregnancy or were in end-stage renal failure. End-stage renal failure was defined as renal failure requiring hemodialysis or renal transplantation. This resulted in a crosssectional analysis of 35,373 visits from 1865 different patients. The number of visits per patient ranged from 1-131; 43% of the patients had less than 10 visits, 22% of the patients had 10-19 visits, and 35% of the patients had more than 20 visits. For this analysis, ESR values were expressed in four categories: less than 25 (normal), 25-50 (mild elevation), 51-75 (moderate elevation), and greater than 75 (marked elevation) mm/h. A subgroup analysis of patients who did not have anti-dsDNA and/or low complement as a feature of their disease was performed, and 5703 visits from 418 different patients were included. The number of visits per patient in this subgroup analysis ranged from 1-97; 55% of the patients had less than 10 visits, 19% had 10-19 visits, and 26% had 20 or more visits.
To assess the relationship between changes in ESR and changes in disease activity, we identified all pairs of cohort visits from the same patient that were separated by 80-100 days. Then we examined the association between changes in ESR between these two visits and concurrent changes in disease activity. This resulted in an analysis of 12,119 pairs of visits from 1386 different patients. The number of paired visits per patient ranged from 1-62; 68% contributed to less than 10 pairs, 20% contributed to 10-19 pairs, and 12% contributed to 20 or more pairs. A subgroup analysis of patients who did not have anti-dsDNA and low complement levels as a feature of their disease was performed, based on 2160 pairs of visits from 293 individuals.
To assess the relationship between changes in ESR and changes at a future visit, we identified all sets of three consecutive visits from each patient where the consecutive visits were separated by 80-100 days. Then we examined the association between changes in ESR between the first two visits, and changes in disease activity between the second and third visit. This resulted in an analysis of 6141 visit triplets from 987 different patients. The number of triplets contributed per patient ranged from 1-45; 78% contributed to less than 10, 17% contributed to 10-19, and 5% contributed 20 or more triplets.
To assess associations we used mixed-effects models to account for the fact that the same patients contributed multiple visits to each analysis.
To assess associations controlling for other predictors, we included terms in the model to adjust for age, ethnicity, gender, body mass index, cholesterol, complement levels, hematocrit, anti-dsDNA, prednisone use, hydroxychloroquine use, and other immunosuppressant use. To make the results easier to interpret, we provide estimates of the expected difference in disease activity measured per one SD change in ESR. In this sample, the SD was approximately 27 mm/h. Table 1 shows the results of the cross-sectional analysis to address the question of whether there is an association between ESR at a visit and the level of disease activity at that same visit. After adjusting for confounding factors, ESR divided into normal, mild, moderate, and severely high categories was positively associated with global measures of disease activity, and all organ-specific measures. Mild, moderate and marked ESR elevations were strongly associated with SELENA-SLEDAI, PGA, rash, renal, joint, hematology, and serositis VAS, as well as with hematuria and proteinuria. The association with the neurological and pulmonary VAS was also statistically significant. Table 2 shows the results of the subgroup analysis which included only the patients with no history of anti-dsDNA or low complement levels. In this important clinical subset of patients, mild, moderate and marked ESR elevations were still positively associated with SLEDAI, PGA, renal and joint VAS. The sensitivity and specificity of ESR elevation (>25 mm/h) for confirming active disease is 56% and 63%, respectively, if high disease activity is defined as SELENA-SLEDAI of 3 or more. For a PGA of 1 or more, ESR elevation (>25 mmHg) has a sensitivity of 49% and specificity of 64%.
Results
Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity G Stojan et al. Table 3 shows the association between changes in ESR and changes in disease activity measures between pairs of consecutive visits separated by 80-100 days. A change in ESR between two visits was highly correlated with a concurrent change in PGA, renal, fatigue and joint VAS (p < 0.0001) and with changes in hematuria or proteinuria, but not with changes in other organ activity indices.
This correlation remained strong after adjustment for changes in body mass index, complement levels, hematocrit, anti-dsDNA levels, and prednisone, hydroxychloroquine or immunosuppressant use. The magnitudes of the associations were small, however. For example, an increase in ESR of one SD was associated with a 0.1 point increase in SELENA-SLEDAI. Table 4 shows the results of the subgroup analysis, which included the patients with no history of anti-dsDNA or low complement levels. In this subgroup, there was no association between changes in ESR and changes in disease activity measures between two consecutive visits. Table 5 shows the results of visit triplet analysis to address the question of whether changes in ESR between the first two visits predicted changes in disease activity between the second and third visits. There was no statistically significant correlation between change in ESR between the first and second visit and change in disease activity in between the second and third visit.
Discussion
The association between elevated ESR and disease activity in SLE has been a matter of controversy over the years because the available data were contradictory. The ESR, for example, is not 17 or the British Isles Lupus Activity Group (BILAG) activity measures, 18 but was included in the SLAM. 10 A longitudinal study of outcome from the multiethnic LUMINA cohort assessed the utility of ESR as a categorical marker of same-day disease activity and damage accrual. They showed that mild (25-50 mm/h), moderate (51-75 mm/h), and marked (>75 mm/h) ESR elevations were strongly associated with global disease activity in SLE measured by SLAM-noESR. 19 The limitations of the LUMINA report included, among others, not being able to ascertain other coexistent conditions that might be associated with increased ESR, for example, infections, malignancy, pregnancy and end-stage renal failure. We were able to address these limitations in our study design. Similar data were obtained in a cross-sectional study from Iran, in which Nasiri et al. described a significant association between increasing ESR and overall BILAG scores in 100 patients with SLE. 20 On the other hand, in a prospective study of 120 SLE patients by Mirzayan et al., 21 elevation of ESR did not predict an increase in the SLEDAI. Chang et al. found no significant association between ESR and physician-reported improvement based on SLAM-R or SLEDAI, but patients with SLE who perceived improvement of their condition were more likely to have lower ESR. 22 In recent years, the continuous search for new biomarkers for assessment of SLE activity has yielded indirect data on their relation to ESR. Viallard and colleagues studied HLA-DR expression by subsets of peripheral T lymphocytes in relation to disease activity in 60 patients with SLE over a 3-year period, using flow cytometric analysis. Thirty-four patients had 'quiescent' disease (SLEDAI scores 1-6 throughout the study) and 26 had active disease (at least a 3-point increase in the SLEDAI score at some point). In univariate analyses, ESR was significantly higher in the active disease group. 23 In a study used to validate the potential utility of serum chemokine levels as biomarkers of disease activity, the chemokine score was significantly associated with disease flare (SLEDAI >3), but none of the common laboratory tests (ESR, complement, anti-dsDNA antibody) were significant predictors of a disease flare, although the ESR showed a positive trend (p ¼ 0.071). 24 In a study in which serum concentrations of neopterin, beta-2-microglobulin, 55 kDtype soluble tumor necrosis factor receptor, soluble interleukin-2 receptor and soluble CD8 were compared with the Index of European Consensus Lupus Activity Measurement (ECLAM), it was found that ESR strongly correlated with ECLAM (p < 0.001). 25 In a study from Brazil that evaluated the association of plasma concentrations of terminal complement complex (SC5b-9) with disease activity, it was found that a significant elevation of ESR was present in SLE patients with moderate/ severe activity compared with those without active disease or with mild disease activity. 26 Present/absent, so difference in means corresponds to differences in probability of presence.
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Our data show that mild, moderate, and marked ESR elevations are strongly associated with disease activity in SLE at the same visit, as measured by SELENA-SLEDAI, PGA and with organ-specific activity including SLEDAI, PGA, rash, renal, joint, hematology, neurological, pulmonary, and serositis VAS, as well as with hematuria and proteinuria. This correlation persisted after adjustment for age, ethnicity, sex, weight, cholesterol, C3, C4, hematocrit, anti-dsDNA, prednisone use, hydroxychloroquine use, and immunosuppressant use. A change in ESR between two visits was also significantly correlated with a change in PGA, renal, fatigue and joint VAS, but not with changes in other organ activity indices. However, the magnitude of the association was small. In the subgroup analysis of patients with no history of anti-dsDNA or low complement levels, ESR categories (normal, mild, moderate, severe) were positively associated with SELENA-SLEDAI, PGA, renal and joint VAS at the same visit but there was no association with changes in disease activity measures between two consecutive visits. Changes in ESR between two visits also did not predict changes in disease activity at a third visit.
Thus, we conclude that, until more specific biomarkers are validated, categorical levels of ESR (normal, mild, moderate, severe) do associate meaningfully with disease activity, including in patients with no anti-dsDNA or low complement. Changes in ESR between two visits do associate statistically with changes in disease activity, but the magnitude is unlikely to be clinically important.
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